InCarda's inhaled flecainide well tolerated in Phase I

InCarda Therapeutics Inc. (San Francisco, Calif.) reported top-line data from an Australian Phase I trial in 40 healthy volunteers showing that single doses of 20-60 mg InRhythm inhaled flecainide were well tolerated. The company also said InRhythm delivered flecainide into systemic circulation within 1-3 minutes, "yielding venous plasma levels sufficient to elicit its expected electrophysiological effects." InCarda is developing the product to treat symptomatic acute episodes paroxysmal atrial fibrillation (AF).

The 2-part trial is evaluating the safety and pharmacokinetics of 3 single ascending doses of InRhythm in 34 healthy volunteers in the double-blind, placebo-controlled part 1 of the trial. Part 2 compared InRhythm to IV flecainide in 6 healthy volunteers...